No Survival Benefit from Adding Cetuximab or Panitumumab to Oxaliplatin-Based Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer in KRAS Wild Type Patients: A Meta-Analysis

BACKGROUND: The efficacy of combined therapies of oxaliplatin-based chemotherapy and anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies (MAbs) remains controversial in colorectal cancer (CRC). The aim of this study is to estimate the efficacy and safety of adding cetuximab or pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Si-wei, Huang, Yuan-yuan, Wei, Ying, Jiang, Zhi-min, Zhang, Yuan-dong, Yang, Qiong, Xie, De-rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3511401/
https://www.ncbi.nlm.nih.gov/pubmed/23226426
http://dx.doi.org/10.1371/journal.pone.0050925

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3511401/
https://www.ncbi.nlm.nih.gov/pubmed/23226426
http://dx.doi.org/10.1371/journal.pone.0050925

Ejemplares similares